Skoči na glavni sadržaj

Izvorni znanstveni članak

https://doi.org/10.3325/cmj.2014.55.446

Contribution of clinical trials to gross domestic product in Hungary

Zoltán Kaló ; Eötvös Loránd University (ELTE), Department of Health Policy and Health Economics, Budapest, Hungary
János Antal ; Parexel Hungary Ltd, Budapest Hungary
Miklós Pénzes ; Eötvös Loránd University (ELTE), Department of Health Policy and Health Economics, Budapest, Hungary
Csilla Pozsgay ; MSD Pharma Hungary, Budapest Pharma Hungary, Budapest, Hungary
Zsuzsanna Szepezdi ; Egis Pharmaceuticals Plc., Budapest, Hungary
László Nagyjánosi ; Syreon Research Institute, Budapest, Hungary


Puni tekst: engleski pdf 91 Kb

str. 446-451

preuzimanja: 695

citiraj


Sažetak

Aim To determine the contribution of clinical trials to the
gross domestic product (GDP) in Hungary.
Methods An anonymous survey of pharmaceutical companies
and clinical research organizations (CROs) was conducted
to estimate their clinical trial-related employment
and revenues. Clinical trial documents at the National Institute
of Pharmacy (NIP) were analyzed to estimate trial-related
revenues at health care institutions and the value of
investigational medical products (IMPs) based on avoided
drug costs. Financial benefits were calculated as 2010 US $
purchasing power parity (PPP) values.
Results Clinical trials increased the revenue of Hungarian
health care providers by US $165.6 million. The value
of IMPs was US $67.0 million. Clinical trial operation and
management activities generated 900 jobs and US $166.9
million in revenue among CROs and pharmaceutical companies.
Conclusions The contribution of clinical trials to the Hungarian
GDP in 2010 amounted to 0.2%. Participation in international
clinical trials may result in health, financial, and
intangible benefits that contribute to the sustainability of
health care systems, especially in countries with severe resource
constraints. Although a conservative approach was
employed to estimate the economic benefits of clinical trials,
further research is necessary to improve the generalizability
of our findings.

Ključne riječi

Hrčak ID:

129948

URI

https://hrcak.srce.hr/129948

Datum izdavanja:

15.10.2014.

Posjeta: 1.158 *